🔎 Trials Near Me

Inicio › Trastorno depresivo mayor › Arkansas

Ensayos clínicos de Trastorno depresivo mayor en Arkansas

15 estudios sobre Trastorno depresivo mayor buscan participantes en Arkansas.

Ciudades en Arkansas

Texto oficial del estudio (inglés)

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  • SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06559306

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

  • Vanda Investigational Site, Little Rock
ReclutandoFase 3
Edades de 18 a 65 · Todos los sexos · Actualizado el 24 sept 2026 · NCT06830044

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

  • Pillar Clinical Research, Bentonville
  • SanRo Clinical Research Group, Bryant
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 8 sept 2026 · NCT07076407

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

  • Draig Clinical Site, Little Rock
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 2 sept 2026 · NCT07610473

A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder

  • SanRo Clinical Research Group LLC WCG Clinical Network, Bryant
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 28 ago 2026 · NCT07573176

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

  • Draig Clinical Site, Bentonville
  • Draig Clinical Site, Little Rock
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 26 ago 2026 · NCT07300969

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Bryant
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 ago 2026 · NCT06911112

A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)

  • Preferred Research Partners, Inc., Little Rock
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 10 ago 2026 · NCT07592689

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  • Woodland International Research Group, Little Rock
  • Woodland Research Northwest, Rogers
ReclutandoFase 3
Edades de 18 a 74 · Todos los sexos · Actualizado el 3 ago 2026 · NCT06775379

Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Bryant
  • Neurocrine Clinical Site, Little Rock
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 jul 2026 · NCT06966401

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

  • Preferred Research Partners /ID# 279206, Little Rock
  • Woodland International Research Group /ID# 277605, Little Rock
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 15 jun 2026 · NCT07276997

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  • Pillar Clinical Research, LLC, Little Rock
  • Preferred Research Partners, Inc., Little Rock
  • Woodland Research Northwest, Rogers
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 11 may 2026 · NCT06524830

Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

  • Neurocrine Clinical Site, Little Rock
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 oct 2025 · NCT06786624

Study of ALTO-300 in MDD

  • Site 193, Rogers
ReclutandoFase 2
Edades de 18 a 70 · Todos los sexos · Actualizado el 24 jul 2025 · NCT05922878

De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.